NASDAQ:BGMS

Cyclacel Pharmaceuticals (BGMS) Stock Price, News & Analysis

Cyclacel Pharmaceuticals logo
$0.61 +0.04 (+6.28%)
Closing price 03:59 PM Eastern
Extended Trading
$0.65 +0.04 (+7.06%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Cyclacel Pharmaceuticals Stock (NASDAQ:BGMS)

Advanced

Key Stats

Today's Range
$0.59
▼
$0.64
50-Day Range
$0.57
▼
$1.05
52-Week Range
$0.57
▼
$2.80
Volume
80,439 shs
Average Volume
19,149 shs
Market Capitalization
$4.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research has centered on compounds that target cell-cycle regulation and other processes involved in cancer-cell growth.

The company’s investigational drug candidates have included fadraciclib, a cyclin-dependent kinase inhibitor, and sapacitabine, an oral nucleoside analogue. These candidates have been studied for potential use in hematologic cancers and solid tumors; they are not approved medicines.

Founded in the United Kingdom, Cyclacel has operated in both the U.K. and the United States. Spiro Rombotis has served as the company’s president and chief executive officer.

AI Generated. May Contain Errors.

Cyclacel Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
19th Percentile Overall Score

BGMS MarketRank™: 
0.941691760195 of 5 stars

Cyclacel Pharmaceuticals scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cyclacel Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Cyclacel Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Cyclacel Pharmaceuticals' stock forecast and price target.
  • Price to Book Value per Share Ratio

    Cyclacel Pharmaceuticals has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.54% of the float of Cyclacel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 1.17, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclacel Pharmaceuticals has recently decreased by 10.18%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cyclacel Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Cyclacel Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Cyclacel Pharmaceuticals has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Industrials companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Cyclacel Pharmaceuticals this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cyclacel Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    23.75% of the stock of Cyclacel Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions.

  • Read more about Cyclacel Pharmaceuticals' insider trading history.
Receive BGMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BGMS Stock News Headlines

Cyclacel Pharmaceuticals (NASDAQ:BGMS) Stock Falls 9.3% - Should You Sell?
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Headlines

BGMS Stock Analysis - Frequently Asked Questions

Cyclacel Pharmaceuticals' stock was trading at $1.48 at the beginning of 2026. Since then, BGMS shares have decreased by 58.7% and is now trading at $0.6109.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) posted its earnings results on Thursday, November, 12th. The company reported ($0.07) earnings per share for the quarter. The business earned $454 thousand during the quarter. Cyclacel Pharmaceuticals had a negative trailing twelve-month return on equity of 24.24% and a negative net margin of 74.40%.

Shares of BGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/12/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Trading Companies & Distributors
Sub-Industry
Trading Companies & Distributors
Current Symbol
NASDAQ:BGMS
CIK
1130166
Employees
12
Year Founded
1996

Profitability

EPS (Trailing Twelve Months)
($2.40)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3 million
Net Margins
-74.40%
Pretax Margin
109.09%
Return on Equity
-24.24%
Return on Assets
-21.39%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.84
Quick Ratio
5.63

Sales & Book Value

Annual Sales
$750 thousand
Price / Sales
5.39
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.01 per share
Price / Book
0.60

Miscellaneous

Outstanding Shares
6,620,000
Free Float
5,050,000
Market Cap
$4.04 million
Optionable
N/A
Beta
-0.44
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:BGMS) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners